4-hydroxy-3-methoxy-N,N-bis(1-methylethyl)benzenecarboxamide | 146978-52-1

• 分子结构分类: 有机化合物 - 苯类化合物 - 酚类
• 英文名称: 4-hydroxy-3-methoxy-N,N-bis(1-methylethyl)benzenecarboxamide
• 英文别名: 4-hydroxy-N, N-diisopropyl-3-methoxybenzamide；4-hydroxy-N,N-diisopropyl-3-methoxybenzamide；4-hydroxy-3-methoxy-N,N-bis(1-methylethyl)benzamide；N,N-diisopropyl-4-hydroxy-3-methoxybenzamide；4-Hydroxy-3-methoxy-N,N-di(propan-2-yl)benzamide
• CAS: 146978-52-1
• 化学式: C₁₄H₂₁NO₃
• 分子量: 251.326
• InChiKey: UGPRLYCCVCFYGT-UHFFFAOYSA-N

物化性质

• 沸点：
  411.1±35.0 °C(Predicted)
• 密度：
  1.074±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3
• 重原子数：
  18
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  49.8
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  4-hydroxy-3-methoxy-N,N-bis(1-methylethyl)benzenecarboxamide 在 potassium carbonate 、 sodium iodide 作用下， 以 丙酮 、 乙腈 为溶剂， 生成 4-(3-Iodopropoxy)-3-methoxy-N,N-di(propan-2-yl)benzamide
  参考文献：
  名称：

  3-Amino-1,2-benzisoxazoles: A new family of potent inhibitors of LTB4 binding to the human neutrophils

  摘要：

  A new family of 3-amino-1,2-benzisoxazoles was designed and synthesized to be a potent inhibitors of LTB(4) binding to the human neutrophils. HS-1141 appears to be one of the strongest inhibitors of LTB(4) binding reported so far (IC50 = 7nM). (C) 1997, Elsevier Science Ltd.

  DOI：

  10.1016/s0960-894x(97)00025-5
• 作为产物：
  描述：

  香草酸 在 氯化亚砜 、 二异丙胺 作用下， 以 二氯甲烷 、 N,N-二甲基甲酰胺 为溶剂， 生成 4-hydroxy-3-methoxy-N,N-bis(1-methylethyl)benzenecarboxamide
  参考文献：
  名称：

  Hydroxyamidine derivatives

  摘要：

  该发明涉及以下式的化合物##STR1##其中C(=NOH)-NH.sub.2基团可能处于互变式形式，以及其药学上可接受的盐，其中：R.sub.1是氨基或经由从脂肪烃基、芳基脂肪烃基、芳基和环脂烃基中选择的取代基单取代或双取代的氨基，或者是经由二价脂肪烃基或被氧中断的所述基团双取代的氨基；R.sub.2是氢、卤素、三氟甲基、脂肪烃基或羟基；或者R.sub.2是经由脂肪醇、芳基醇或芳香醇乙醚化的羟基，或者是经由脂肪或芳基羧酸酯化的羟基；或者R.sub.2是经由被羧基置换的脂肪醇乙醚化的羟基，或者是被酯化羧基或酰胺基羧基置换的脂肪醇乙醚化的羟基；X.sub.1和X.sub.3互相独立地是氧(--O--)或硫(--S--)；X.sub.2是可由芳基中断的二价脂肪烃基；R.sub.3和R.sub.4互相独立地是氢、卤素、三氟甲基、脂肪烃基、羟基或者经由脂肪醇乙醚化的羟基，或者是经由脂肪或芳基羧酸酯化的羟基；在上述定义中，芳基可能是，互相独立地，进一步经由卤素、三氟甲基、脂肪烃基、羟基和经由脂肪醇乙醚化或经由脂肪或芳基羧酸酯化的羟基中选择的一个或多个取代基取代；其中环脂烃基可能被脂肪基取代。这些化合物在哺乳动物中对于对LTB.sub.4受体拮抗剂具有选择性，并用于治疗对LTB.sub.4受体拮抗作用产生反应的病症或综合征。

  公开号：

  US05455274A1
• 作为试剂：
  描述：

  ethyl 4-[5-bromopentoxy]benzenecarboximidoate 、 4-hydroxy-3-methoxy-N,N-bis(1-methylethyl)benzenecarboxamide 在 4-hydroxy-3-methoxy-N,N-bis(1-methylethyl)benzenecarboxamide 作用下， 生成 ethyl 4-[5-[2-methoxy-4-[N,N-bis(1-methylethyl)aminocarbonyl]phenoxy]pentoxy]benzenecarboximidoate
  参考文献：
  名称：

  Amidino compounds, their manufacture and methods of treatment

  摘要：

  本发明涉及公式 ##STR1## 中化合物，其中C(.dbd.NH)--NHR.sub.3基团可以处于互变异构或同分异构形式，并且其药学上可接受的盐。该化合物可用作选择性LTB.sub.4受体拮抗剂。

  公开号：

  US05451700A1

文献信息

• Amidino compounds, their manufacture and method of treatment
  申请人：Ciba-Geigy Corporation

  公开号：US05488160A1

  公开（公告）日：1996-01-30

  The invention relates to the compounds of the formula ##STR1##

  这项发明涉及公式##STR1##的化合物。
• Novel diether compounds inhibiting differentiation of osteoclasts
  作者：Kyung Eun Doh、Ju-Hee Kang、Zheng Ting、Mijung Yim、Hea-Young Park Choo

  DOI：10.1007/s12272-015-0672-x

  日期：2016.2

  Osteoporosis is a disorder in which bone mass decreases and is responsible for many degenerative bone diseases. The excessive formation and activity of osteoclasts results in pathological disorders of the bone. Receptor Activator of Nuclear Factor κB Ligand (RANKL) is regarded as a key regulator of osteoclast activity and as a new therapeutic target for treating osteoporosis. Herein, we have synthesized several new small molecules and tested their inhibition activity on RANKL-induced osteoclast formation. The active compounds 2c and 4d showed inhibitory activity against RANKL-induced osteoclast differentiation (IC50 = 1.56 and 2.20 μM, respectively). The most active compound 2c prevented LPS-induced osteoclastogenesis in vivo. These data imply that the compound may be the potential candidate for a new therapeutic drug for treatment of bone resorption-associated diseases.

  骨质疏松是一种骨量减少的疾病，导致多种退行性骨病的发生。破骨细胞的过度形成和活跃性会导致骨骼的病理性紊乱。核因子κB配体受体激活因子（RANKL）被认为是破骨细胞活性的关键调节因子，也是治疗骨质疏松的新疗法靶点。在此，我们合成了几种新型小分子，并测试了它们对RANKL诱导的破骨细胞形成的抑制活性。活性化合物2c和4d对RANKL诱导的破骨细胞分化表现出抑制活性（IC50分别为1.56和2.20 μM）。最活跃的化合物2c在体内防止了LPS诱导的破骨细胞生成。这些数据表明，该化合物可能是治疗与骨吸收相关疾病的新型候选药物。
• 3-amino-1,2-benzoisoxazole derivatives, process for preparation, and use
  申请人：Dong Wha Pharm. Ind. Co., Ltd.

  公开号：US06150390A1

  公开（公告）日：2000-11-21

  The present invention relates to a novel 3-amino-1,2-benzoisoxazole derivatives, represented by Formula I, LTB-4[leukotriene-B-4; 5(S),12(R)-dihydroxy-6,14-cis-8,10-trans-eicosatetraenoic acid] receptor antagonist, process for preparation thereof, and use thereof for LTB-4 receptor antagonist or therapeutics for osteoporosis. ##STR1## (in which n is integer of 3-5).

  本发明涉及一种新型的3-氨基-1,2-苯并异噁唑衍生物，由式I表示，即LTB-4[白三烯-B-4; 5(S),12(R)-二羟基-6,14-顺式-8,10-反式-二十碳四烯酸]受体拮抗剂，其制备方法以及用途，用于LTB-4受体拮抗剂或治疗骨质疏松症。##STR1##（其中n为3-5的整数）。
• NEW COMPOUNDS FOR ALLEVIATION, PREVENTION OR TREATMENT OF OSTEOPOROSIS, THE PREPARATION THEREOF AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME
  申请人：PARKCHOO Hea-Young

  公开号：US20130040999A1

  公开（公告）日：2013-02-14

  The present invention provides novel compounds of Chemical Formula I, a pharmaceutically acceptable salt thereof, or a hydrate or solvate thereof, a preparation thereof and a composition for the alleviation, prevention or treatment of osteoporosis, comprising thereof in an effective amount, and a method for alleviating, preventing or treating osteoporosis.

  本发明提供了化学式I的新化合物，其药用盐，或其水合物或溶剂合物，以及其制备方法和用于缓解、预防或治疗骨质疏松症的组合物，其中所述化合物以有效量存在，并提供了一种缓解、预防或治疗骨质疏松症的方法。
• Amidino compounds, their manufacture and use as medicament
  申请人：CIBA-GEIGY AG

  公开号：EP0518819A2

  公开（公告）日：1992-12-16

  The invention relates to the compounds of the formula and pharmaceutically acceptable salts thereof, in which : R1 is amino which is mono- or disubstituted by a substituent selected from an aliphatic hydrocarbon radical, an araliphatic hydrocarbon radical, an aromatic radical, and a cycloaliphatic hydrocarbon radical or is amino which is disubstituted by a divalent aliphatic hydrocarbon radical ; R2 is hydrogen, halogen, trifluoromethyl, an aliphatic hydrocarbon radical, or is hydroxy which is etherified by an aliphatic alcohol, araliphatic alcohol, or aromatic alcohol or which is esterified by an aliphatic or araliphatic carboxylic acid ; R3 is hydrogen or an acyl radical which is derived from an organic carbonic acid, un organic carboxylic acid, a sulfonic acid, or a carbamic acid ; X1 and X3, independently of one another, are oxygen (-O-) or sulphur (-S-) ; and X2 is a divalent aliphatic hydrocarbon radical which may be interrupted by an aromatic radical ; wherein the phenyl rings of formula I may be, independently of one another, further substituted by one or more substituents selected from halogen, trifluoromethyl, un aliphatic hydrocarbon radical, hydroxy, and hydroxy which is etherified by an aliphatic alcohol or which is esterified by an aliphatic or araliphatic carboxylic acid ; wherein aryl in the above definitions may be, independently of one another, further substituted by one or more substituents selected from halogen, trifluoromethyl, un aliphatic hydrocarbon radical, hydroxy, and hydroxy which is etherified by an aliphatic alcohol or which is esterified by an aliphatic or araliphatic carboxylic acid ; wherein a cycloaliphatic hydrocarbon radical may be substituted by an aliphatic radical. The compounds are useful as selective LTB-4 receptor antagonists in the treatment of conditions or syndromes in mammals which are responsive to LTB-4 receptor antagonism.

  本发明涉及如下式的化合物 及其药学上可接受的盐，其中： R1 是被选自脂族烃基、脂肪族烃基、芳香族基和环脂族烃基的取代基单取代或二取代的氨基，或者是被二价脂族烃基二取代的氨基； R2 是氢、卤素、三氟甲基、脂肪族烃基，或者是被脂肪族醇、脂肪族醇或芳香族醇醚化的羟基，或者是被脂肪族或脂肪族羧酸酯化的羟基； R3 是氢或由有机碳酸、有机羧酸、磺酸或氨基甲酸衍生的酰基； X1 和 X3 各自是氧 (-O-) 或硫 (-S-)；以及 X2 是可被芳香基打断的二价脂族烃基； 其中，式 I 的苯基环可相互独立地进一步被一个或多个取代基取代，这些取代基可选 自卤素、三氟甲基、非脂族烃基、羟基和被脂族醇醚化或被脂族或芳香族羧酸酯化的羟基； 其中，上述定义中的芳基可相互独立地进一步被一个或多个取代基取代，这些取代基选自卤素、三氟甲基、非脂族烃基、羟基和被脂族醇醚化或被脂族或脂肪族羧酸酯化的羟基； 其中环脂族烃基可被脂肪族基取代。这些化合物可作为选择性LTB-4受体拮抗剂，用于治疗哺乳动物体内对LTB-4受体拮抗剂有反应的病症或综合征。